Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
about
Topical tacrolimus for atopic dermatitisPimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infantsVulvovaginal-gingival syndrome.Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomesSystematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.Pharmacotherapy of allergic eye disease.Clinical review of 202 patients with vulval lichen sclerosus: A possible association with psoriasis.Pimecrolimus, yet another intriguing topical immunomodulator.The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review.An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.Association between exposure to topical tacrolimus or pimecrolimus and cancers.Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors.Pharmacotherapy of corneal transplantation.New agents for treating dry eye syndrome.Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs.Suspected malignant transformation of B lymphocytes in the equine cornea from immune-mediated keratitis.FKBP51 protects 661w cell culture from staurosporine-induced apoptosis.Treating atopic dermatitis: safety, efficacy, and patient acceptability of a ceramide hyaluronic acid emollient foam.Treating ocular surface disease: new agents in developmentCost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National HealTacrolimus-induced hyperpigmentation in a patch of vitiligo.Topical tacrolimus, triamcinolone acetonide, and placebo in oral lichen planus: a pilot randomized controlled trial.Genital lichen sclerosus in childhood and adolescence-a retrospective case series of 15 patients: early diagnosis is crucial to avoid long-term sequelae.Atopic dermatitis: a review of topical nonsteroid therapy.A retrospective analysis of pediatric patients with lichen sclerosus treated with a standard protocol of class I topical corticosteroid and topical calcineurin inhibitor.Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis
P2860
Q24186624-7BAD735A-2CAC-499C-87C5-EFD872DE0BDFQ28086973-52685E27-E7A4-4FD2-ADAB-92DCC111A3A2Q34108942-6E4B6D67-93F0-42CA-8AF4-E3C350F2A0B2Q35036840-29FDD0CC-2BA6-46B7-B29D-6B15C513F859Q36042131-0EC298D3-4550-4F47-95F2-D7918EA04C5CQ36491809-66178D7B-FD50-40DF-8B1B-F46E3128B7A2Q36707588-1FF28996-7F0F-46E0-B975-F0A1CDAC2785Q36835586-0BAD7F27-AE58-4520-B84D-E93F398F49E5Q36940038-508BF2E7-EAC9-43D5-B436-2BD3D9E0FFDFQ37049990-554BCD36-6286-4FA8-82BA-2827B18D1DA8Q37630829-3E4C84EE-50D7-4896-A3A5-29426945EC65Q37861867-FD906772-0B95-4420-B039-046EFD7514E2Q37994335-0F2DE589-7B93-4A3B-B7AC-63450227EDCEQ38058002-AEF7E929-F4B5-48AA-9B8E-B9DF94ABD06DQ38266892-AFA9FA83-55CE-4A22-8322-85CD49F7665BQ39013473-E00384DF-5B82-469E-B583-2B52B8C6251BQ39535549-0DC4F8D7-1ACF-47AD-8A19-BC62F02F69F6Q42126636-0B0AE60A-63B1-45F5-9902-37E3D5C20833Q42729437-DC5CB311-0608-4EBC-96FC-391983BE3274Q44513075-99DDBCDD-E13C-4340-AB71-8E5F84CF814CQ46713566-B6FC70C8-EA8B-4BFF-9CB5-337A54B441C7Q48268268-EC007933-A5FC-4DFC-8B44-909B4E14EBB2Q50259795-290BACE0-CF47-42FC-BB98-195CF64EBDACQ52597622-2C8FB4EA-E5D8-46D3-B0F7-33A63E2DD541Q53442647-2C164700-9AA3-4B69-B3B1-7EDAD3888585Q57266992-FDFABF92-A74B-4879-BA86-D9C349EF9237
P2860
Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
@en
Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
@nl
type
label
Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
@en
Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
@nl
prefLabel
Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
@en
Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
@nl
P2860
P1476
Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
@en
P2093
Ormerod AD
P2860
P304
P356
10.1111/J.1365-2133.2005.06899.X
P407
P577
2005-10-01T00:00:00Z